Stifel Nicolaus Cuts ALX Oncology (NASDAQ:ALXO) Price Target to $1.50

ALX Oncology (NASDAQ:ALXO) had its target price reduced by Stifel Nicolaus from $3.00 to $1.50 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a hold rating on the stock.

ALXO has been the subject of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of ALX Oncology in a research report on Friday. Piper Sandler lifted their price target on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday. UBS Group lowered their price target on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Finally, Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and lifted their price target for the company from $2.00 to $3.00 in a research report on Thursday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.14.

ALX Oncology Trading Down 19.1 %

Shares of ALXO opened at $1.06 on Friday. ALX Oncology has a 1-year low of $0.95 and a 1-year high of $17.83. The firm has a market capitalization of $55.91 million, a price-to-earnings ratio of -0.36 and a beta of 1.01. The firm’s 50-day moving average price is $1.39 and its 200-day moving average price is $1.60. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALXO. Privium Fund Management B.V. raised its holdings in ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after buying an additional 112,093 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of ALX Oncology during the third quarter valued at approximately $469,000. GSA Capital Partners LLP purchased a new position in shares of ALX Oncology during the third quarter valued at approximately $88,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of ALX Oncology by 207.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company’s stock valued at $151,000 after purchasing an additional 56,028 shares during the last quarter. Finally, Walleye Capital LLC raised its holdings in shares of ALX Oncology by 110.3% during the third quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock valued at $420,000 after purchasing an additional 121,113 shares during the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.